Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 17/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15943519 | 0.88 | RYR2 (0.46) | RYR2 | |
| SCHEMBL806953 | 0.86 | RYR2 (0.63) | RYR2 | |
| SCHEMBL6866663 | 0.86 | RYR2 (0.46) | RYR2 | |
| SCHEMBL15705417 | 0.86 | RYR2 (0.43) | RYR2 | |
| SCHEMBL12894395 | 0.85 | RYR2 (0.45) | RYR2 | |
| SCHEMBL6867950 | 0.75 | RYR2 (0.65) | RYR2 | |
| SCHEMBL3428843 | 0.75 | RYR2 (0.67) | RYR2 | |
| SCHEMBL26344276 | 0.73 | RYR2 (0.53) | RYR2 | |
| SCHEMBL26344322 | 0.73 | RYR2 (0.58) | RYR2 | |
| SCHEMBL9635185 | 0.73 | RYR2 (0.49) | RYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | disclosed |
| US-20230302013-A1 | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-09-28 | — | — | US | disclosed |
| US-9573914-B2 | Process for preparing benzothiazepines from gamma-aminoalkylbenzenes | LES LABORATOIRES SERVIER (FR) | 2017-02-21 | — | — | US | disclosed |
| US-20140187536-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140121368-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8710045-B2 | Agents for preventing and treating disorders involving modulation of the ryanodine receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-04-29 | — | — | US | disclosed |
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121368-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | TPMT, SULT2A1, GABRA4 | RYR2 564/4885ALDH1A1 55/4885KDM4E 135/4885 |
| US-20230302013-A1 | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS | RYR2, RYR1, CACNB1 | RYR2 1/4885ALDH1A1 4722/4885KDM4E 1496/4885 |
| US-20140187536-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | RYR2, RYR1, FKBP3 | RYR2 1/4885ALDH1A1 4462/4885KDM4E 1686/4885 |
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | RYR1, RYR2, ATP2A1 | RYR2 2/4885ALDH1A1 1225/4885KDM4E 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.